An Outcomes Comparison Between Holmium Laser Enucleation of the Prostate, Open Simple Prostatectomy, and Robotic Simple Prostatectomy for Large Gland Benign Prostatic Hypertrophy.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
03 2023
Historique:
received: 24 08 2022
revised: 13 11 2022
accepted: 14 12 2022
pubmed: 1 1 2023
medline: 28 3 2023
entrez: 31 12 2022
Statut: ppublish

Résumé

To compare perioperative outcomes between Holmium laser enucleation of the prostate (HoLEP), open simple prostatectomy (OSP), and robotic simple prostatectomy (RSP) for large prostates (> 80 cc). A retrospective study of 340 patients who underwent HoLEP (n = 209), OSP (n = 66), or RSP (n = 65) at a large academic medical center between January 2013 - September 2021 was performed. Length of stay (LOS), operative time, catheter duration, estimated blood loss (EBL), blood transfusion, and 30-day ED visits and readmissions were compared between the three groups. Univariate analyses consisted of ANOVA with Tukey's corrections and Chi-square tests. Linear and multivariate logistic regression was also performed. All tests were two-sided and a p-value <0.05 was pre-determined to be statistically significant. Analyses were performed with SAS v9.4. HoLEP was found to have the shortest: operative time (1.4 vs 2.7 vs 3.8h), LOS (0.65 vs 4.2 vs 2.6d), and catheter duration (0.38 vs 9.9 vs 11.2d) compared to OSP and RSP, respectively (all P <.0001). HoLEP also had the lowest EBL (66 vs 795 vs 326 mL, P <.0001). HoLEP and RSP had a lower risk of blood transfusion compared to OSP (P <.0001). These associations remained significant on multivariable analyses. HoLEP is a minimally invasive treatment option for large prostates that was found to have shorter operative time, LOS, and catheter duration as well as lower EBL compared to OSP and RSP.

Identifiants

pubmed: 36586427
pii: S0090-4295(22)01082-2
doi: 10.1016/j.urology.2022.12.018
pii:
doi:

Substances chimiques

Holmium W1XX32SQN1

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

180-186

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Matthew S Lee (MS)

Department of Urology, The Ohio State University, Columbus OH. Electronic address: Matthew.lee@osumc.edu.

Mark A Assmus (MA)

The University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada.

Meera Ganesh (M)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Josh Han (J)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Jessica Helon (J)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Quan Mai (Q)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Xinlei Mi (X)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Amy E Krambeck (AE)

Department of Urology, The Feinberg School of Medicine, Northwestern University, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH